- Patent Title: RET inhibitor for use in treating cancer having a RET alteration
-
Application No.: US17061743Application Date: 2020-10-02
-
Publication No.: US11963958B2Publication Date: 2024-04-23
- Inventor: Erica Evans Raab , Beni B. Wolf
- Applicant: Rigel Pharmaceuticals, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Rigel Pharmaceuticals, Inc.
- Current Assignee: Rigel Pharmaceuticals, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Goodwin Procter LLP
- Main IPC: A61K31/506
- IPC: A61K31/506 ; A61K9/00 ; A61P35/00 ; A61P35/04
Abstract:
Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
Public/Granted literature
- US20210085680A1 RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION Public/Granted day:2021-03-25
Information query
IPC分类:
